Approval reinstates gefitinib as a therapy for lung cancer

Article Type

Article

Changed

Fri, 01/04/2019 - 11:11

Display Headline

Approval reinstates gefitinib as a therapy for lung cancer

Author(s)

Edited Jame Abraham

Report Prepared Jane De Lartigue

This past summer, the United States joined more than 60 countries worldwide in approving the epidermal growth factor receptor (EGFR) inhibitor gefitinib for the treatment of patients with non-small-cell lung cancer (NSCLC) who harbor certain EGFR mutations. The approval marked “restoration of fortune” for the drug, which originally received accelerated approval from the US Food and Drug Administration (FDA) in 2003 for the treatment of advanced NSCLC after progression on platinum doublet chemotherapy and docetaxel but was voluntarily withdrawn from the market after subsequent confirmatory randomized trials failed to verify a survival benefit.

Click on the PDF icon at the top of this introduction to read the full article.

Article PDF

JCSO_nov_385_de_Lartigue.pdf

Issue

The Journal of Community and Supportive Oncology - 13(11)

Publications

The Journal of Community and Supportive Oncology

MDedge Hematology and Oncology

Topics

Lung Cancer

Page Number

385-387

Legacy Keywords

non-small-cell lung cancer, NSCLC, EGFR, epidermal growth factor receptor, ISEL study, gefitinibtyrosine kinase inhibitor, TKI

Sections

Community Translations

Author(s)

Edited Jame Abraham

Report Prepared Jane De Lartigue

Author(s)

Edited Jame Abraham

Report Prepared Jane De Lartigue

Article PDF

JCSO_nov_385_de_Lartigue.pdf

Article PDF

JCSO_nov_385_de_Lartigue.pdf

This past summer, the United States joined more than 60 countries worldwide in approving the epidermal growth factor receptor (EGFR) inhibitor gefitinib for the treatment of patients with non-small-cell lung cancer (NSCLC) who harbor certain EGFR mutations. The approval marked “restoration of fortune” for the drug, which originally received accelerated approval from the US Food and Drug Administration (FDA) in 2003 for the treatment of advanced NSCLC after progression on platinum doublet chemotherapy and docetaxel but was voluntarily withdrawn from the market after subsequent confirmatory randomized trials failed to verify a survival benefit.

Click on the PDF icon at the top of this introduction to read the full article.

This past summer, the United States joined more than 60 countries worldwide in approving the epidermal growth factor receptor (EGFR) inhibitor gefitinib for the treatment of patients with non-small-cell lung cancer (NSCLC) who harbor certain EGFR mutations. The approval marked “restoration of fortune” for the drug, which originally received accelerated approval from the US Food and Drug Administration (FDA) in 2003 for the treatment of advanced NSCLC after progression on platinum doublet chemotherapy and docetaxel but was voluntarily withdrawn from the market after subsequent confirmatory randomized trials failed to verify a survival benefit.

Click on the PDF icon at the top of this introduction to read the full article.

Issue

The Journal of Community and Supportive Oncology - 13(11)

Issue

The Journal of Community and Supportive Oncology - 13(11)

Page Number

385-387

Page Number

385-387

Publications

The Journal of Community and Supportive Oncology

MDedge Hematology and Oncology